Crinetics Pharmaceuticals (CRNX) Reports In-Line Q4 EPS

Crinetics Pharmaceuticals (NASDAQ: CRNX) reported Q4 EPS of ($0.88), in-line with the analyst estimate of ($0.88).

For earnings history and earnings-related data on Crinetics Pharmaceuticals (CRNX) click here.

You May Also Be Interested In

• Regency Centers (REG) Tops Q2 EPS by 2c
• ExxonMobil Q2 profit falls short of forecasts, shares slide
• Heritage Global to wind down specialty lending unit, expects material charge